FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
NATCOPHARM Share Price Target
Natco Pharma Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
NATCOPHARM Share Price *
594.5 +7.3 (1.24%)
* (quote may be delayed)
NATCOPHARM Share Price Forecast - Consensus
| No. of reports in last year | 8 |
| No. of analysts | 4 |
| Average Consensus Forecast | 650.50 |
| Consensus Potential | 8.04% |
NATCOPHARM Share Price Target - Broker Reports - 2019
Nirmal Bang
13-Aug-19
Price @ Call: 545.45
Target: 654
BUY
We estimate these opportunities can translate to Rs2000mn to Rs4000mn in sales for NPL over the next 3 years. In Brazil too, NPL is anticipating new approvals in the coming months which should allow it to double current run rate from Rs300mn per quarter. We have retained Buy rating on the stock with a target price (TP) of Rs654, up 19% from the CMP.
AnandRathi
9-Aug-19
Price @ Call: 543.49
Target: 763
BUY
With niche product launches, Natco’s India, Brazil and Canada businesses would do well, we believe. However, its revenue, EBITDA and PAT are likely to be flat over FY19-21 due to the high base for gTamiflu, though to some extent likely to be counter-balanced by gCopaxone. Beyond FY21, however, we expect a few niche launches to drive earnings. We retain a Buy on the stock, with a target of Rs 763.
Geojit Financial Services
31-May-19
Price @ Call: 515.9
Target: 487
SELL
At current CMP of Rs516, NATCO is trading at a P/E of 13x on FY21E EPS. We believe that increasing copaxone market share and better results from EM’s will sustain the earnings growth going forward. We project domestic/ export formulations to grow at ~7/6% CAGR over FY19-21E and expect margins to stabilize around 39% in FY21E. However, considering no major launches in FY20, we value at 12x on FY21E EPS and downgrade the rating to sell from hold with a revised target price of Rs487.
ICICIdirect.com
29-May-19
Price @ Call: 530.5
Target: 595
HOLD
The bright spot for Natco is of course its strong balance sheet besides the management’s abilityto carve out niche out of the available opportunities. The growth trajectory is likely to improve from FY22 onwards as the new strategy settles down. We value the stock on an SOTP basis. Accordingly, we arrive at our new target price of | 595, which includes base business value of ~| 400 (15x FY21E EPS of | 26.7) + | 195 for NPV of FTF/Para IVs in the US.
Nirmal Bang
29-May-19
Price @ Call: 530.5
Target: 654
BUY
Based on the revised forecasts, we have cut our target price on NPL to Rs654 (from Rs779 earlier) and retained Buy rating on the stock. NPL has given guidance of high single-digit growth in net earnings for FY20, which is expected to be largely driven by rest of world markets (Canada and Brazil) and India. These markets put together should post high-teen growth. As regards limited competition portfolio in the US, the company does not assume incremental competition in Copaxone generic, at least until the end of CY20.
Nirmal Bang
18-Feb-19
Price @ Call: 575.95
Target: 776
BUY
ICICIdirect.com
15-Feb-19
Price @ Call: 606.8
Target: 635
HOLD
Geojit Financial Services
15-Feb-19
Price @ Call: 592.5
Target: 640
HOLD
NATCOPHARM Share Price Target - Broker Reports - 2018
Geojit Financial Services
21-Nov-18
Price @ Call: 732.6
Target: 842
BUY
AnandRathi
16-Nov-18
Price @ Call: 736.13
Target: 930
BUY
Nirmal Bang
12-Nov-18
Price @ Call: 755.74
Target: 813
ACCUMULATE
Geojit Financial Services
27-Aug-18
Price @ Call: 759.15
Target: 831
ACCUMULATE
ICICIdirect.com
9-Aug-18
Price @ Call: 812.85
Target: 860
HOLD
ICICIdirect.com
25-May-18
Price @ Call: 804.27
Target: 860
HOLD
Geojit Financial Services
9-Apr-18
Price @ Call: 780
Target: 908
BUY
NATCOPHARM Share Price Target - Broker Reports - 2017
Karvy Stock Broking
11-Dec-17
Price @ Call: 949.84
Target: 1132
BUY
Axis Direct
10-Nov-17
Price @ Call: 911.85
Target: 1150
BUY
Reliance Securities
23-Oct-17
Price @ Call: 988.1
Target: 1200
BUY
Axis Direct
13-Oct-17
Price @ Call: 989.7
Target: 1240
BUY
ICICIdirect.com
5-Oct-17
Price @ Call: 954.35
Target: 1065
BUY
ICICIdirect.com
9-Aug-17
Price @ Call: 925.25
Target: 955
HOLD
ICICIdirect.com
31-May-17
Price @ Call: 942
Target: 1055
BUY
Nirmal Bang
28-Feb-17
Price @ Call: 809.65
Target: 725
SELL
Axis Direct
23-Feb-17
Price @ Call: 803
Target: 830
BUY
Religare
16-Feb-17
Price @ Call: 771.2
Target: 655
SELL
ICICIdirect.com
15-Feb-17
Price @ Call: 768
Target: 870
BUY
NATCOPHARM Share Price Target - Broker Reports - 2016
Kotak Securities
30-Dec-16
Price @ Call: 592.15
Target: 750
BUY
Axis Direct
8-Dec-16
Price @ Call: 592
Target: 725
BUY
ICICIdirect.com
16-Nov-16
Price @ Call: 650
Target: 750
BUY
Precision Technicals
30-Aug-16
Price @ Call: 682.5
Target: 780
BUY
Edelweiss
10-Aug-16
Price @ Call: 634
Target: 640
BUY
ICICIdirect.com
27-May-16
Price @ Call: 463
Target: 600
BUY